The recent evaluation of the efficacy of homeopathic medicines by the French High Authority for Health (HAS) mainly focused on the medicine, yet homeopathy is a therapy which should be evaluated as a whole. After having described the main characteristics of this therapy, the examination of the results obtained in different clinical situations examined by the HAS enables clinical evaluation proposals to be put forward, with observational studies and clinical trials adapted to the therapy's key singularity: the individualisation of the treatment. The continued integration of homeopathic medicine in the French health system and its reimbursement is an essential condition for ensuring the development of research and patient safety.